Eris Lifesciences Limited has informed stock exchanges about an upcoming virtual investor meeting scheduled for December 18, 2025, as per the requirements of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Meeting Details

The pharmaceutical company has provided comprehensive details about the scheduled investor interaction:

Institutional Participants

The investor meeting will see participation from several prominent institutional investors and asset management companies. The confirmed participants include:

• Axis Mutual Fund
• ICICI Prudential Asset Management
• Universal Sompo General Insurance Company Limited

Regulatory Compliance and Disclosure

The company has emphasized its commitment to regulatory compliance and transparency in its communication to BSE Limited and National Stock Exchange of India Limited. Eris Lifesciences has clarified that the meeting schedule is indicative and subject to changes due to any unforeseen developments.

Importantly, the company has stated that discussions during the investor interaction will be based solely on publicly available documents. The management has explicitly confirmed that no unpublished price-sensitive information (UPSI) is intended to be discussed during the meeting, ensuring compliance with insider trading regulations.

Company Information

The notification was signed by Milind Talegaonkar, Company Secretary and Compliance Officer (Membership No: A26493), and submitted to both major stock exchanges where the company is listed. Eris Lifesciences trades on BSE with security code 540596 and on NSE with the symbol ERIS.

The company maintains its registered corporate office at Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad-380054, and operates under CIN: L24232GJ2007PLC049867.

Eris Lifesciences has demonstrated strong financial performance, with its EBITDA margin expanding from 32% in FY23 to 36% in H1FY26. This growth is attributed to strategic acquisitions and operational efficiency.

Financial Highlights

Key Growth Drivers

1. Strategic Acquisitions:

   • Biocon's insulin business
   • Swiss Parenterals

2. Market Position:

   • Top-5 player in anti-diabetes therapy
   • 6.00% overall market share
   • 15.00% share in insulins

3. EU-CDMO Contract:

   • First contract secured
   • Revenue visibility of ₹150.00-200.00 crores in FY27

Financial Performance Analysis

Examining the quarterly data:

The company has shown significant improvement across all key financial metrics, with notable growth in net profit and EPS.

Strategic Implications

1. Diversification: The acquisition of Biocon's insulin business strengthens Eris Lifesciences' position in the diabetes market.

2. International Expansion: The EU-CDMO contract marks the company's entry into the European market, potentially opening up new revenue streams.

3. Margin Improvement: The expansion in EBITDA margin suggests improved operational efficiency and potential synergies from recent acquisitions.

Outlook

With its strong market position in the anti-diabetes segment and strategic moves into international markets, Eris Lifesciences appears well-positioned for continued growth. The company's ability to improve profitability while expanding its product portfolio and geographical reach is a positive indicator for future performance.

Investors should monitor the integration of recent acquisitions and the execution of the EU-CDMO contract, as these will be crucial for sustaining the current growth trajectory.

Note: Investors are advised to conduct their own research and consult financial advisors before making investment decisions.